読み込み中
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
前日終値
$140.58
+$7.97 · +6.01%
日中の時刻はETです。市場データは遅延する場合があります。
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
日中レンジ
現在 $140.58
52週レンジ
現在 $140.58
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
53
適正価値
センチメント
38
弱気
リスク
80
高リスク
モメンタム
51
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
日中レンジ
現在 $140.58
52週レンジ
現在 $140.58
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.47億 USD | 1.26億 USD | 9310.5万 USD | 5555万 USD | 1461.2万 USD |
| 売上原価 | 2.1億 USD | 2.04億 USD | 1.89億 USD | 1.72億 USD | 1.15億 USD |
| 粗利益 | −6257.3万 USD | −7802.2万 USD | −9561.1万 USD | −1.16億 USD | −1億 USD |
| 研究開発 | 1.96億 USD | 3.22億 USD | 3.39億 USD | 3.3億 USD | 4.6億 USD |
| 販売・一般管理 | 2.76億 USD | 3.68億 USD | 3.63億 USD | 2.96億 USD | 2.34億 USD |
| 営業費用 | 4.72億 USD | 21.11億 USD | 14.2億 USD | 53.26億 USD | 11.65億 USD |
| 受取利息 | 2865.2万 USD | 2673.3万 USD | 795.4万 USD | 174万 USD | 33.2万 USD |
| 減価償却費と償却費 | 1.56億 USD | 1.58億 USD | 1.59億 USD | 1.55億 USD | 5844.9万 USD |
| 営業利益 | −5.34億 USD | −21.89億 USD | −15.15億 USD | −54.43億 USD | −12.65億 USD |
| 純利益 | −4.08億 USD | −20.27億 USD | −14.66億 USD | −53.99億 USD | −12.48億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$106.14
下落余地（24.50%）この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM1.44億0.18%787.4億 USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI1.32億1.33%98.74億 USD0.35%$153.77+3.00%
Vanguard Morningstar Total Stock Market ETFVTI9777.5万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Biotechnology ETFIBB4332.4万0.41%108.2億 USD0.44%$206.49+3.00%
Dimensional - US Small Cap ETFDFAS3710.41万0.11%338.69億 USD0.31%$78.35+0.32%
Schwab U.S. Small-Cap ETFSCHA3144.58万0.14%218.24億 USD0.03%$32.79+0.40%
Vanguard Extended Market ETFVXF3001.84万0.03%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO1884.7万0.10%180億 USD0.06%$112.66+0.50%iShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASSchwab U.S. Small-Cap ETFSCHAVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
